Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms
Fig 2
Evaluation of fibrotic markers and clinical parameters in IPF subsets.
A. Expression of fibrosis markers in IPF subsets based on the analysis in Fig 1 in GSE47460 (Kaminski-LGRC bulk expression cohort) [14–17] as compared to healthy controls (‘Control’). Adjusted p values determined by ANOVA and post-hoc Dunn’s test are reported on plots. B. Distribution of clinical parameters in IPF subsets based on the analysis in Fig 1 as reported in GSE47460 (Kaminski-LGRC bulk expression cohort) [14–17] as compared to healthy controls (‘Control’). %DLCO, FVC and FEV1 values represent pre-lung transplant values reported in GSE47460 (Kaminski-LGRC bulk expression cohort) [14–17]. Adjusted p values determined by ANOVA and post-hoc Dunn’s test are reported on plots.